<DOC>
	<DOCNO>NCT02058147</DOCNO>
	<brief_summary>Primary Objective : To compare insulin glargine/lixisenatide fix ratio combination lixisenatide alone insulin glargine alone ( top metformin treatment ) glycated hemoglobin ( HbA1c ) change baseline Week 30 . Secondary Objective : To compare overall efficacy safety insulin glargine/lixisenatide fix ratio combination ( FRC ) insulin glargine alone lixisenatide alone ( top metformin treatment ) 30 week treatment period participant type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Safety Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared Insulin Glargine Alone Lixisenatide Alone Top Metformin Patients With T2DM</brief_title>
	<detailed_description>Approximately 37 week include 6 week screen , 30-week treatment period , 3 day follow-up period .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Participants type 2 diabetes mellitus diagnose least 1 year screen visit , treat least 3 month prior visit 1 metformin alone metformin second oral antidiabetic treatment could sulfonylurea , glinide , sodium glucose cotransporter2 inhibitor dipeptidyl peptidase 4 ( DPP4 ) inhibitor , adequately control treatment . Signed write informed consent . Exclusion criterion : HbA1c screen visit : le 7.5 % 10 % participant previously treat metformin alone , less 7.0 % 9 % participant previously treat metformin second oral antidiabetic treatment . Pregnancy lactation , woman childbearing potential effective contraceptive method . Use oral glucoselowering agent state inclusion criterion injectable glucoselowering agent 3 month screen . Previous Treatment insulin ( except shortterm treatment due intercurrent illness include gestational diabetes , discretion trial physician ) . History discontinuation previous treatment glucagonlike peptide ( GLP1 ) receptor agonist ( GLP1 RA ) due safety/tolerability issue lack efficacy . Participant previously participate clinical trial lixisenatide insulin glargine/lixisenatide fix ratio combination previously receive lixisenatide . Any contraindication metformin use , accord local labeling . Use weight loss drug within 3 month prior screen visit . Within last 6 month prior screen visit : history stroke , myocardial infarction , unstable angina , heart failure require hospitalization . Planned coronary , carotid peripheral artery revascularisation procedure perform study period . History pancreatitis ( unless pancreatitis relate gallstone cholecystectomy already perform ) , chronic pancreatitis , pancreatitis previous treatment incretin therapy , pancreatectomy , stomach/gastric surgery . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( e.g , multiple endocrine neoplasia syndrome ) . Uncontrolled inadequately control hypertension ( systolic blood pressure 180 mmHg diastolic blood pressure 95 mmHg ) screen visit . At screen visit , Body Mass Index ( BMI ) less equal 20 40 kg/m^2 . At screen visit amylase and/or lipase 3 time upper limit normal ( ULN ) laboratory range . At screen visit alanine aminotransferase ( ALT ) alkaline phosphatase ( AST ) 3 ULN . At screen visit calcitonin equal 20 pg/mL ( 5.9 pmol/L ) . Exclusion Criteria randomization end screen period : HbA1c le 7 % 10 % ; Fasting Plasma glucose 250 mg/dL ( 13.9 mmol/L ) ; Metformin maximal tolerate dose less 1500 mg/day ; Amylase and/or lipase 3 ULN . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>